NASDAQ:ELAB PMGC (ELAB) Stock Price, News & Analysis $2.02 -0.15 (-6.71%) As of 12:38 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About PMGC Stock (NASDAQ:ELAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PMGC alerts:Sign Up Key Stats Today's Range$2.03▼$2.1450-Day Range$1.67▼$14.0052-Week Range$1.62▼$309.12Volume124,350 shsAverage Volume5.33 million shsMarket Capitalization$2.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California. Read More PMGC Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreELAB MarketRank™: PMGC scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingPMGC has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePMGC has received no research coverage in the past 90 days.Read more about PMGC's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PMGC is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PMGC is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPMGC has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted35.83% of the float of PMGC has been sold short.Short Interest Ratio / Days to CoverPMGC has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PMGC has recently decreased by 74.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPMGC does not currently pay a dividend.Dividend GrowthPMGC does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 16 people have searched for ELAB on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat Follows2 people have added PMGC to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PMGC insiders have not sold or bought any company stock.Percentage Held by Insiders0.14% of the stock of PMGC is held by insiders.Percentage Held by Institutions22.22% of the stock of PMGC is held by institutions.Read more about PMGC's insider trading history. Receive ELAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PMGC and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELAB Stock News HeadlinesUPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use ...April 29, 2026 | markets.businessinsider.comUPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological DisordersApril 28, 2026 | globenewswire.comIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - preparing to underwrite what insiders are calling 'Project Apex.' A June timeline is now widely expected. Dr. Mark Skousen, Macroeconomic Strategist at The Oxford Club, says nearly 15,000 investors have already found a 'backdoor' pre-IPO position - and he's sharing his top pick at no cost before the roadshow begins.May 8 at 1:00 AM | The Oxford Club (Ad)NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in HumansApril 28, 2026 | globenewswire.comNorthStrive Defense Tech Acquires Patented GPS-Denied Autonomous Drone Navigation Technology Option, Built for Defense and Counter-Unmanned Aircraft SystemsApril 23, 2026 | globenewswire.comUnivest Securities, LLC Announces a $40 Million Equity Line Facility for its Client PMGC Holdings, Inc. (NASDAQ: ELAB)April 22, 2026 | markets.businessinsider.comSVM Machining, Inc. Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products Co., Inc.April 21, 2026 | globenewswire.comPMGC Holdings secures $40 million equity facility to fund acquisitionsApril 17, 2026 | msn.comSee More Headlines ELAB Stock Analysis - Frequently Asked Questions How have ELAB shares performed this year? PMGC's stock was trading at $35.52 at the beginning of the year. Since then, ELAB shares have decreased by 94.3% and is now trading at $2.0150. How were PMGC's earnings last quarter? PMGC Holdings Inc. (NASDAQ:ELAB) released its earnings results on Monday, March, 30th. The company reported ($52.76) earnings per share (EPS) for the quarter. The company had revenue of $0.30 million for the quarter. When did PMGC's stock split? PMGC's stock reverse split on Tuesday, March 10th 2026.The 1-6 reverse split was announced on Wednesday, March 4th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 9th 2026. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did PMGC IPO? PMGC (ELAB) raised $6 million in an initial public offering (IPO) on Tuesday, November 21st 2023. The company issued 1,500,000 shares at a price of $4.00 per share. Univest Securities acted as the underwriter for the IPO. How do I buy shares of PMGC? Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PMGC own? Based on aggregate information from My MarketBeat watchlists, some other companies that PMGC investors own include BIOLASE (BIOL), CDT Equity (CDT), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII). Company Calendar Last Earnings3/30/2026Today5/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ELAB's financial health is in the Yellow zone, according to TradeSmith. ELAB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMulti-Sector Conglomerates Industry DIVERSIFIED OPS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELAB Previous SymbolNASDAQ:ELAB CIK1840563 Webelevaiskincare.com Phone866-794-4940FaxN/AEmployees18Year FoundedN/AProfitability EPS (Trailing Twelve Months)($400.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.75 million Net MarginsN/A Pretax Margin-1,313.56% Return on Equity-92.90% Return on Assets-67.56% Debt Debt-to-Equity Ratio0.01 Current Ratio1.74 Quick Ratio1.72 Sales & Book Value Annual Sales$590 thousand Price / Sales3.96 Cash FlowN/A Price / Cash FlowN/A Book Value$93.33 per share Price / Book0.02Miscellaneous Outstanding Shares1,160,000Free Float1,157,000Market Cap$2.34 million OptionableN/A Beta-0.27 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ELAB) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored$1,170 monthly from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMGC Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMGC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.